Dr. Lorraine Nolan:

As Mr. Breslin outlined, an extensive planning process has been in train in the past two years. At this point, we are working with the companies involved. In many cases, we will have sufficient alternatives to those medicines and will not necessarily be reliant on them. This is part of the criticality assessment exercise on which we are working. If it comes down to dependency on a medicine, we are open to looking at pragmatic ways to transition across the period after Brexit to allow supply to continue to the market.